Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PHGE

BiomX Inc

0.2320

Jul 10 • 04:00PM ET -0.0480 (-17.14%)

Industrials Aerospace & Defense USA Nano AMEX

Jul 10, 2:02 PMDilution fears from July 8 acquisition LOI drive BiomX (PHGE) 20.61% drop on July 10

Peers: CMMB COCP HCWB HIND INAB LEXX MTVA NCEL OSRH XCUR

Scroll to Statements

Index	-
Market Cap	2.74M
Enterprise Value	20.19M
Income	-47.77M
Sales	0.00M
Book/sh	-2.48
Cash/sh	0.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	20
IPO	Mar 13, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	2.34
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.24
Current Ratio	1.24
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-24.96
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	50.25% 38.28%
Sales past 3/5Y	- -
EPS Y/Y TTM	-92.20%
Sales Y/Y TTM	-
EPS Q/Q	-17.22%
Sales Q/Q	-
Earnings	Apr 01
EPS/Sales Surpr.	1.69% -

Insider Own	27.29%
Insider Trans	-33.86%
Inst Own	1.54%
Inst Trans	-0.30%
ROA	-182.66%
ROE	-354.26%
ROIC	-1971.06%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-43.92%
SMA50	-64.11%
SMA200	-94.55%
Trades

Shs Outstand	11.80M
Shs Float	8.58M
Short Float	10.83%
Short Ratio	0.12
Short Interest	0.93M
52W High	14.71 -98.42%
52W Low	0.24 -4.57%
Volatility	14.96% 13.52%
ATR (14)	0.09
RSI (14)	26.98
Beta	1.32
Rel Volume	1.24
Avg Volume	7.64M
Volume	9,506,257

Perf Week	-27.27%
Perf Month	-65.96%
Perf Quarter	-92.24%
Perf Half Y	-89.26%
Perf YTD	-87.59%
Perf Year	-97.02%
Perf 3Y	-99.68%
Perf 5Y	-99.98%
Perf 10Y	-
Recom	2.00
Target Price	399.00
Prev Close	0.28
Price	0.23
Change	-17.14%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-21	Initiated	Ladenburg Thalmann	Buy	$25

Jul-10-26 07:25AM	BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities (GlobeNewswire) -17.14%
Jul-08-26 07:05AM	BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities (GlobeNewswire) -8.37%
Jul-06-26 08:32AM	BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement (GlobeNewswire) -5.33%
Jun-24-26 08:38AM	BiomX: Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026 (GlobeNewswire) -9.75%
Jun-18-26 09:15AM	BiomX Provides Update on Defense Technology Portfolio and Growth Strategy (GlobeNewswire) -5.47%
09:00AM	Loading…
Jun-12-26 09:00AM	BiomX Announces NYSE American Acceptance of Plan to Regain Compliance (GlobeNewswire) -24.24%
Jun-11-26 09:03AM	BiomX: Zorronet's AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global Events (GlobeNewswire) +10.63%
Jun-02-26 09:32AM	Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit (GlobeNewswire) -15.83%
Jun-01-26 09:25AM	Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence (GlobeNewswire) -17.46%
May-27-26 09:40AM	BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations (GlobeNewswire)
May-06-26 04:15PM	BiomX's Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand (GlobeNewswire) -5.71%
Apr-16-26 04:30PM	Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems (GlobeNewswire) -6.60%
Apr-13-26 09:20AM	BiomX Accelerates Defense Technology Buildout with DFSL Acquisition (GlobeNewswire) -9.00%
Apr-10-26 08:30AM	BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications (GlobeNewswire)
Mar-31-26 10:48AM	BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System (GlobeNewswire) -16.39%
09:28AM	Loading…
Mar-30-26 09:28AM	BiomX Adds Former Mossad Deputy to Advisory Board (GlobeNewswire)
Mar-27-26 04:30PM	BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency (GlobeNewswire)
Mar-26-26 08:48AM	BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations (GlobeNewswire)
Mar-25-26 01:10PM	Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets (Barrons.com)
Mar-19-26 09:15AM	BiomX CEO Issues Letter to Stockholders (PR Newswire)
Mar-09-26 09:00AM	BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth (PR Newswire) +8.96%
Jan-27-26 01:41PM	BiomX Issues Statement Regarding Recent Common Stock Trading Activity (GlobeNewswire) +69.51%
01:18PM	BiomX (PHGE) Stock Surges: A Single Buyer Now Owns Nearly 20% (Benzinga)
Dec-30-25 08:15AM	BiomX announces $3M private placement (TipRanks) -7.00%
Dec-29-25 12:00PM	All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy (Zacks)
08:00AM	BiomX Announces $3.0 Million Private Placement (GlobeNewswire)
Dec-08-25 07:30AM	BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review (GlobeNewswire) -36.94%
Nov-25-25 04:40PM	BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis (GlobeNewswire) +5.37% -18.69%
Nov-14-25 04:31PM	BiomX Inc. Announces 1-for-19 Reverse Stock Split (GlobeNewswire) +7.46% -15.87%
Nov-12-25 04:02PM	BiomX Inc (PHGE) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -6.99%
07:30AM	Loading…
07:30AM	BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates (GlobeNewswire)
Nov-05-25 08:30AM	BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025 (GlobeNewswire)
Nov-04-25 08:40AM	BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections (GlobeNewswire) -16.85%
Oct-17-25 08:30AM	BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways (GlobeNewswire)
Sep-04-25 08:30AM	BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-19-25 08:19AM	BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis (GlobeNewswire)
Aug-13-25 06:30AM	BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates (GlobeNewswire) -11.69%
Aug-06-25 08:30AM	BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 (GlobeNewswire) +49.43%
Jul-14-25 09:00AM	BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis (GlobeNewswire)
Jul-08-25 08:30AM	BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis (GlobeNewswire)
May-19-25 10:02AM	BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference (GlobeNewswire)
May-16-25 03:13AM	BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
May-15-25 06:30AM	BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates (GlobeNewswire)
May-08-25 07:00AM	BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 (GlobeNewswire)
Apr-18-25 09:55AM	BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-01-25 06:30AM	BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure (GlobeNewswire) -11.28%
Mar-31-25 06:30AM	BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) (GlobeNewswire)
Mar-25-25 06:30AM	BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) -7.17%
Mar-19-25 12:35PM	BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 (GlobeNewswire)
Feb-26-25 08:00AM	BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million (GlobeNewswire) -14.03%
Dec-16-24 08:00AM	BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards (GlobeNewswire)
Nov-14-24 06:30AM	BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire)
Nov-12-24 12:20PM	BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024 (GlobeNewswire)
Oct-16-24 07:05AM	BiomX announces mandatory unit separation (TipRanks)
Oct-15-24 07:00AM	BiomX Announces a Mandatory Unit Separation (GlobeNewswire)
Sep-18-24 08:00AM	BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-04-24 08:00AM	BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 08:00AM	BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024 (GlobeNewswire) -7.38%
Aug-16-24 10:55AM	UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Aug-15-24 06:30AM	BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) -11.58%
06:30AM	BiomX Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Aug-08-24 07:00AM	BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024 (GlobeNewswire)
Jul-29-24 07:00AM	BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance (GlobeNewswire) -5.27%
Jul-10-24 06:30AM	BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock (GlobeNewswire) +8.20%
May-30-24 04:50PM	BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) +19.43%
07:00AM	BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024 (GlobeNewswire)
May-21-24 06:30AM	BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) +6.85%
May-15-24 07:00AM	BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024 (GlobeNewswire)
May-06-24 07:00AM	BiomX to Present at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +6.28%
Apr-23-24 08:00AM	BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) (GlobeNewswire) +17.42%
Apr-18-24 08:00AM	BiomX Announces the Appointment of Susan Blum to its Board of Directors (GlobeNewswire) +5.61%
Apr-05-24 09:55AM	Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-04-24 07:49AM	BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure (GlobeNewswire) +8.57%
Apr-03-24 06:30AM	BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.90%
Mar-27-24 06:30AM	BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024 (GlobeNewswire) +6.07%
Mar-19-24 05:00AM	Telum Therapeutics appoints Dr. Subhendu Basu as CEO (PR Newswire)
Mar-18-24 06:30AM	BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire)
Mar-06-24 07:30AM	BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire) +197.66%
Jan-04-24 08:00AM	BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-30-23 04:15PM	BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023 (GlobeNewswire) -13.67%
Nov-29-23 06:30AM	BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire) -46.43%
Nov-14-23 06:30AM	BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 08:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-18-23 08:00AM	BiomX Announces the Appointment of Edward L. Williams to its Board of Directors (GlobeNewswire)
Oct-04-23 06:34AM	BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Sep-07-23 09:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023 (GlobeNewswire)
Sep-06-23 04:05PM	BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 06:30AM	BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -9.29%
Aug-02-23 04:30PM	BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023 (GlobeNewswire)
Jun-08-23 05:00PM	NYSE American Initiates Delisting Proceedings for BiomX Warrants (GlobeNewswire)
May-31-23 03:00AM	BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC) (GlobeNewswire) +13.56%
May-15-23 06:30AM	BiomX Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.17%
May-12-23 08:00AM	BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors (GlobeNewswire) +9.97%
May-08-23 06:30AM	BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023 (GlobeNewswire)
May-05-23 06:30AM	BiomX Announces Second Closing of $7.5 Million Private Placement (GlobeNewswire) +7.18%
Mar-29-23 06:30AM	BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-27-23 07:00AM	BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023 (GlobeNewswire) +7.00%
Feb-22-23 06:35AM	BiomX Announces $7.5 Million Private Placement (GlobeNewswire)
06:30AM	BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-29-22 09:10AM	BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage (GlobeNewswire) +6.50%

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.

CEO & DirectorMr. Michael Oster

Scientific FounderProf. Rotem Sorek Ph.D.

Ph.D.Dr. Eran Elinav M.D.

Ph.D.Dr. Timothy K. Lu M.D.

Scientific FounderDr. Carl R. Merril M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Yeganeh Reuven	Director	Mar 17 '26	Sale	5.00	530,000	2,650,000	Mar 18 05:47 PM
Yeganeh Reuven	Director	Mar 16 '26	Sale	5.00	450,000	2,250,000	Mar 18 05:47 PM
Yeganeh Reuven	Director	Mar 13 '26	Sale	5.00	370,000	1,850,000	Mar 13 04:30 PM
Yeganeh Reuven	Director	Mar 12 '26	Sale	5.00	300,000	1,500,000	Mar 13 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHGE

BiomX Inc

Upgrade your Finviz experience